Welcome to our dedicated page for 60 Degrees Pharmaceuticals Warrant news (Ticker: SXTPW), a resource for investors and traders seeking the latest updates and insights on 60 Degrees Pharmaceuticals Warrant stock.
60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The firm's pipeline products under development cover development programs for COVID-19, fungal, tick-borne, and other viral diseases.
Recent achievements include their Chief Executive Officer, Geoff Dow, PhD, planning a clinical trial to study the use of tafenoquine in treating human babesiosis, a tick-borne disease. The Company has been focused on developing new medicines for rare infectious diseases and collaborating with renowned research organizations in the U.S., Australia, and Singapore.
Financially, 60 Degrees Pharmaceuticals recently reported results for the first fiscal quarter of 2024, showcasing a strong commitment to advancing treatments for infectious diseases.
News
Rhea-AI Summary
60 Degrees Pharmaceuticals, Inc. will sponsor a pilot study by North Carolina State University in 2024 to evaluate tafenoquine for the treatment of babesiosis in dogs, a condition where standard of care fails in 20% of cases. The drug resistance issue is also addressed as the standard of care is expensive.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
60 Degrees Pharmaceuticals, Inc. announces FDA's delay in commenting on babesiosis trial, but maintains June 1, 2024, start date. Tafenoquine, an anti-malarial ingredient, is in focus.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
60 Degrees Pharmaceuticals, Inc. announces sponsorship of animal studies to investigate tafenoquine's efficacy against Candida auris, a drug-resistant fungal pathogen. Monash University will conduct the studies starting in the second quarter of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
60 Degrees Pharmaceuticals, Inc. appoints Kristen Landon as Chief Commercial Officer to lead U.S. relaunch of ARAKODA® for malaria prevention. The company plans to expand clinical research in tick-borne diseases beyond acute babesiosis. Landon brings over 26 years of commercial leadership experience in the pharmaceutical industry.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
News
Rhea-AI Summary
WallachBeth Capital LLC announced that 60 Degrees Pharmaceuticals, Inc. completed a Public Offering of 5,260,901 units and 999,076 pre‑funded units at specific prices. The underwriters were granted an option to purchase additional shares, Warrants, and/or Pre-Funded Warrants. WallachBeth Capital LLC partially exercised its over-allotment option with respect to 818,177 Warrants.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) announced the closing of its public offering of 5,260,901 units and 999,076 pre-funded units. The company intends to use the net proceeds for working capital, relaunch of ARAKODA®, and research and development activities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
News
Rhea-AI Summary
WallachBeth Capital LLC announced the pricing of 60 Degrees Pharmaceuticals, Inc.'s public offering of units and pre-funded units. The Units were priced at $0.385 per unit, and the Pre-Funded Units were priced at $0.375 per unit. The offering is expected to close soon.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
60 Degrees Pharmaceuticals, Inc. announced the pricing of its public offering of 5,260,901 units and 999,076 pre-funded units at $0.385 and $0.375 per unit respectively. Each unit consists of one share of common stock and one warrant exercisable for one share of common stock. The offering is expected to close soon.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) plans to conduct a pivotal clinical study for the treatment of hospitalized babesiosis patients with tafenoquine following a Type C meeting with FDA. The FDA indicated that the proposed study could be sufficient for regulatory approval, provided the Company uses a clinical endpoint rather than a surrogate marker. Patient enrollment is expected to begin in the summer of 2024. The company aims to address the unmet medical need for a new therapeutic for hospitalized babesiosis patients, with an estimated 47,000 cases per year in the U.S. Tafenoquine is currently approved for malaria prophylaxis and has been assessed in multiple trials for safety.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) has announced that it has regained compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market after receiving a written notice from the Nasdaq Listing Qualifications Staff. The Company was previously notified of non-compliance due to its common stock failing to maintain a minimum bid price of $1.00 for 30 consecutive business days. However, it has now achieved compliance by maintaining a minimum closing bid price of $1.00 or more for at least 10 consecutive trading days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
FAQ
What is the current stock price of 60 Degrees Pharmaceuticals Warrant (SXTPW)?
The current stock price of 60 Degrees Pharmaceuticals Warrant (SXTPW) is $0.0364 as of December 24, 2024.
What is 60 Degrees Pharmaceuticals focused on?
60 Degrees Pharmaceuticals is focused on developing new medicines for the prevention and treatment of infectious diseases.
What recent achievement did 60 Degrees Pharmaceuticals announce?
60 Degrees Pharmaceuticals announced a clinical trial to study the use of tafenoquine in treating human babesiosis.
Who is leading the efforts at 60 Degrees Pharmaceuticals?
Geoff Dow, PhD, is the Chief Executive Officer of 60 Degrees Pharmaceuticals.
60 Degrees Pharmaceuticals, Inc. Warrant
Nasdaq:SXTPW
SXTPW Rankings
SXTPW Stock Data
1.86M
Medicinal and Botanical Manufacturing
Pharmaceutical Preparations
United States of America
WASHINGTON